F. Capstick et al., VERY-LOW-CALORIE DIET (VLCD) - A USEFUL ALTERNATIVE IN THE TREATMENT OF THE OBESE NIDDM PATIENT, Diabetes research and clinical practice, 36(2), 1997, pp. 105-111
Conventional treatment of obese noninsulin dependent diabetes mellitus
(NIDDM) patients is often unsatisfactory. In this study the efficacy
of Modifast(R), a commercial very low calorie diet (VLCD), was evaluat
ed in a population of obese poorly controlled NIDDM patients. The mech
anisms of action of VLCD in these patients were also studied by compar
ing: (i) Plasma insulin and glucose profiles after a VLCD and an isoca
loric mixed meal and (ii) plasma amino acid levels, both at baseline a
nd after four weeks of VLCD treatment. A total of 14 obese NIDDM patie
nts (M/F 7/7, median body mass index (BMI) 38.7 kg(-2), interquartile
range (IQ) 34.7-46.5 kg(-2), waist circumference 116 cm, IQ 106-139 cm
, insulin treated 7/14) with poor diabetic control (HbA(1c) 8.6%, IQ 7
.8-10%) were studied. Patients were given a VLCD (425 kcal/day) for 12
weeks. At baseline, VLCD and isocaloric meal tests were performed on
consecutive mornings. Fasting plasma amino acid levels were also deter
mined at baseline and after 4 weeks of VLCD treatment. Weight, waist c
ircumference, HbA(1c), blood pressure, fasting plasma insulin, total c
holesterol and triglyceride levels all fell significantly following VL
CD treatment. Insulin therapy was able to be ceased in the seven insul
in treated patients. Oral hypoglycaemic agent dosage fell from a media
n of eight (IQ 6-12) to two (IQ 0-8) tablets per day (P = 0.03) in pat
ients initially on this form of therapy. Insulin secretion was higher
after VLCD than isocaloric meal (P = 0.04). Fasting plasma alanine lev
el fell from 512.0 (IQ 412.0-563.0) to 374.0 (IQ 342-472.0) mu mol/l (
P = 0.04) following VLCD treatment. In conclusion, the short term use
of a VLCD is very effective in rapidly improving glycaemic control and
promoting substantial weight loss in obese NIDDM patients. Moreover,
a VLCD diet increases insulin secretion and reduces substrate for gluc
oneogenesis. Thus, VLCD treatment may improve glycaemic control by fac
tors more than caloric restriction alone. (C) 1997 Elsevier Science Ir
eland Ltd.